ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
6,013.13
-1.71%
US Tech 100
21,039.16
-2.09%
다우존스 지수
43,428.02
-1.69%
Bitcoin
95,510.96
-0.79%
Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ

  6. Phathom Pharmaceuticals Inc (PHAT) 시세

Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals Inc (PHAT)

NASDAQ
5.67
0.13
(2.35%)
마감 24 2월 6:00AM
15분 지연
5.77
0.10
(1.76%)
시간외 거래: 8:56AM
15분 지연

개인 투자자를 위한 전문가급 도구.

프리미엄

주요 통계 및 세부정보

가격
5.77
매수가
5.67
매도가
5.73
거래량
723,073
5.53 일간 변동폭 5.755
5.21 52주 범위 19.71
market_cap
394.537M
전일 종가
5.54
개장가
5.59
최근 거래 시간
30
@
5.67
마지막 거래 시간
재정 규모
US$ 4,058,239
VWAP
5.6125
평균 볼륨(3m)
996,802
발행 주식
68,377,379
배당수익률
-
주가수익률
-1.93
주당순이익(EPS)
-2.95
매출
682k
순이익
-201.59M

Phathom Pharmaceuticals Inc 정보

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small molecule potassium competitive acid blocker medicine that ... Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection. 더 보기

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
www.phathompharma.com
본부
Wilmington, Delaware, USA
설립됨
-
Phathom Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker PHAT. The last closing price for Phathom Pharmaceuticals was US$5.54. Over the last year, Phathom Pharmaceuticals shares have traded in a share price range of US$ 5.21 to US$ 19.71.

Phathom Pharmaceuticals currently has 68,377,379 shares in issue. The market capitalisation of Phathom Pharmaceuticals is US$378.81 million. Phathom Pharmaceuticals has a price to earnings ratio (PE ratio) of -1.93.

PHAT 최신 뉴스

추가 뉴스

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
24 1월 2025
PHAT (2.35%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
21 12월 2024
PHAT (2.35%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
16 12월 2024
PHAT (2.35%)

Form 8-K - Current report
Edgar (US Regulatory)
11 12월 2024
PHAT (2.35%)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Edgar (US Regulatory)
13 11월 2024
PHAT (2.35%)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
08 11월 2024
PHAT (2.35%)

Form 8-K - Current report
Edgar (US Regulatory)
07 11월 2024
PHAT (2.35%)
기간변동변동 %시가고가저가평균 일일 거래량VWAP
1-0.23-3.8333333333366.215.4959669585.71499371CS
4-1.38-19.30069930077.157.255.2110419835.95277417CS
12-3.13-35.16853932588.99.795.219968027.10813031CS
26-7.12-55.23661753312.8919.715.21117542011.79733451CS
52-4.16-41.89325276949.9319.715.2194717611.36025702CS
156-12.28-68.033240997218.0519.715.2155457010.66621302CS
260-37.24-86.58451522943.0164.545.2137227613.15200544CS

PHAT - Frequently Asked Questions (FAQ)

What is the current Phathom Pharmaceuticals share price?
The current share price of Phathom Pharmaceuticals is US$ 5.77
How many Phathom Pharmaceuticals shares are in issue?
Phathom Pharmaceuticals has 68,377,379 shares in issue
What is the market cap of Phathom Pharmaceuticals?
The market capitalisation of Phathom Pharmaceuticals is USD 378.81M
What is the 1 year trading range for Phathom Pharmaceuticals share price?
Phathom Pharmaceuticals has traded in the range of US$ 5.21 to US$ 19.71 during the past year
What is the PE ratio of Phathom Pharmaceuticals?
The price to earnings ratio of Phathom Pharmaceuticals is -1.93
What is the cash to sales ratio of Phathom Pharmaceuticals?
The cash to sales ratio of Phathom Pharmaceuticals is 569
What is the reporting currency for Phathom Pharmaceuticals?
Phathom Pharmaceuticals reports financial results in USD
What is the latest annual turnover for Phathom Pharmaceuticals?
The latest annual turnover of Phathom Pharmaceuticals is USD 682k
What is the latest annual profit for Phathom Pharmaceuticals?
The latest annual profit of Phathom Pharmaceuticals is USD -201.59M
What is the registered address of Phathom Pharmaceuticals?
The registered address for Phathom Pharmaceuticals is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Phathom Pharmaceuticals website address?
The website address for Phathom Pharmaceuticals is www.phathompharma.com
Which industry sector does Phathom Pharmaceuticals operate in?
Phathom Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
MLGOMicroAlgo Inc
US$ 6.3767
(454.50%)
531.54M
BOXLBoxlight Corporation
US$ 3.1099
(51.70%)
1.84M
GDEVGDEV Inc
US$ 20.90
(46.56%)
264.44k
IVVDInvivyd Inc
US$ 1.7501
(44.64%)
37.75M
UPCUniverse Pharmaceuticals Inc
US$ 0.2003
(40.56%)
420.21M
DOYUDouYu International Holdings Ltd
US$ 7.19
(-55.31%)
1.28M
MNDRMobile health Network Solutions
US$ 0.5048
(-46.29%)
18.61M
BLUEbluebird bio Inc
US$ 4.09
(-41.90%)
5.44M
FLDFold Holdings Inc
US$ 6.95
(-37.39%)
488.54k
GCLGCL Global Holdings Ltd
US$ 3.83
(-31.48%)
635.26k
MLGOMicroAlgo Inc
US$ 6.3767
(454.50%)
531.54M
UPCUniverse Pharmaceuticals Inc
US$ 0.2003
(40.56%)
420.21M
ADTXAditxt Inc
US$ 0.0922
(-22.39%)
278.25M
NVDANVIDIA Corporation
US$ 134.43
(-4.05%)
228.14M
HOLOMicroCloud Hologram Inc
US$ 1.565
(31.51%)
190.81M

PHAT Discussion

게시물 보기
rolvram rolvram 3 월 전
Blackrock keeps accumulating
https://stockzoa.com/ticker/phat/ownership/blackrock/#google_vignette
👍️0
Monksdream Monksdream 5 월 전
PHAT new 52=high

👍️0
MiamiGent MiamiGent 7 월 전
PHAT Nice! Account increased 11%! Was stacked.
👍️0
MiamiGent MiamiGent 7 월 전
PHAT 28.5% Revenue beat!
👍️0
MiamiGent MiamiGent 7 월 전
PHAT Still in.
👍️0
FALCON1 FALCON1 7 월 전
https://www.zacks.com/stock/news/2300964/the-zacks-analyst-blog-highlights-danaher-morgan-stanley-pfizer-elite-pharmaceuticals-and-oil-dri

https://www.zacks.com/stock/news/2300922/zacks-initiates-coverage-of-elite-pharmaceuticals-with-outperform-recommendation
👍️0
MiamiGent MiamiGent 7 월 전
HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $28 Price Target
BENZINGA

Jul-19-2024 6:41 a.m. ET

HC Wainwright & Co. analyst Matthew Caufield reiterates Phathom Pharmaceuticals (PHAT) with a Buy and maintains $28 price target.
👍️0
MiamiGent MiamiGent 7 월 전
PHAT I'm hanging in!
👍️0
MiamiGent MiamiGent 7 월 전
BRIEF-Phathom Pharmaceuticals Announces FDA Approval Of Voquezna® (Vonoprazan) Tablets For The Relief Of Heartburn Associated With Non-Erosive Gerd In Adults
REUTERS

Jul-18-2024 8:41 a.m. ET

July 18 (Reuters) - Phathom Pharmaceuticals Inc (PHAT) :

* PHATHOM PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF VOQUEZNA® (VONOPRAZAN) TABLETS FOR THE RELIEF OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GERD IN ADULTS

* PHATHOM PHARMACEUTICALS INC (PHAT): VOQUEZNA MET ITS PRIMARY ENDPOINT IN ITS PHASE 3 PIVOTAL TRIAL Source text for Eikon: Further company coverage:
👍️0
MiamiGent MiamiGent 7 월 전
$PHAT FLE.
👍️0
MiamiGent MiamiGent 7 월 전
PHAT In @ 12.60's
👍️0
Monksdream Monksdream 10 월 전
PHAT under $10
👍️0
Monksdream Monksdream 12 월 전
PHAT 10Q due March 7
👍️0

최근 히스토리

NASDAQ
PHAT
Phathom Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유

광고 제거

광고 없는 경험을 위해 가입하세요

광고 없음

지금 사용해 보세요

광고 유지